Kriya Yoga's simplified techniques cause no hardships or austerities, and were developed for householders as well as for monks. Kriya Yoga is non-sectarian. Its simplified techniques cause no ...
A new study published in npj Mental Health Research provides evidence that breath-based meditation, specifically Sudarshan Kriya Yoga, alters brain rhythms in a way that may support relaxation and ...
Kriya Yoga , which is a simple, scientific and one of the fastest paths for spiritual progress, not only heals an individual emotionally, physically and mentally, but also bestows infinite benefits on ...
Kriya is a biopharmaceutical company developing gene therapy to address common diseases that impact millions of people worldwide. Learn more.
Kriya is developing a portfolio of one-time gene therapies in ophthalmology, metabolic disease and neurology.
Since its founding in October 2019, Kriya has raised over $600 million in committed capital—and with this financing, Kriya’s cash runway is anticipated to run into late 2026. Kriya is developing a portfolio of transformational gene therapies focused on three main therapeutic areas: ophthalmology, neurology and metabolic disease.
Kriya Announces $150 Million Addition to its Series C, Bringing Total ...
Careers Kriya is Changing the Future of Gene Therapy We have an ambitious set of goals, but our confidence – and our inspiration – stems from our people. From California to North Carolina, our teammates bring creativity, leadership, and a spirit of collaboration to their work every day.
Kriya is developing KRIYA 839, a potential one-time gene therapy for type 1 diabetes expressing insulin and glucokinase, designed to be delivered intramuscularly with the objective of driving durable glycemic control and reducing or eliminating the need for exogenous insulin. Kriya is initially evaluating its gene therapy in type 1 diabetes.